Keck School Faculty

Judith G. Villablanca, MD
Judith G. Villablanca, MD
Clinical Professor of Pediatrics (Part-Time)
Pediatrics
CHL Mail Stop 54 Off Campus Los Angeles

Phase I study of vorinostat in combination with isotretinoin in patients with refractory/recurrent neuroblastoma: A new approaches to Neuroblastoma Therapy (NANT) trial Pediatr Blood Cancer. 2018 Jul; 65(7):e27023. . View in PubMed

Predictors of response, progression-free survival, and overall survival using NANT Response Criteria (v10) in relapsed and refractory high-risk neuroblastoma. Pediatr Blood Cancer. 2018 May; 65(5):e26940. . View in PubMed

Phase I study of vorinostat in combination with isotretinoin in patients with refractory/recurrent neuroblastoma: A new approaches to Neuroblastoma Therapy (NANT) trial Pediatr Blood Cancer. 2018 Mar 30; e27023. . View in PubMed

Expression of Five Neuroblastoma Genes in Bone Marrow or Blood of Patients with Relapsed/Refractory Neuroblastoma Provides a New Biomarker for Disease and Prognosis Clin Cancer Res. 2017 Sep 15; 23(18):5374-5383. . View in PubMed

Revisions to the International Neuroblastoma Response Criteria: A Consensus Statement From the National Cancer Institute Clinical Trials Planning Meeting J Clin Oncol. 2017 Aug 01; 35(22):2580-2587. . View in PubMed

A Phase I New Approaches to Neuroblastoma Therapy Study of Buthionine Sulfoximine and Melphalan With Autologous Stem Cells for Recurrent/Refractory High-Risk Neuroblastoma Pediatr Blood Cancer. 2016 08; 63(8):1349-56. . View in PubMed

Different outcomes for relapsed versus refractory neuroblastoma after therapy with (131)I-metaiodobenzylguanidine ((131)I-MIBG) Eur J Cancer. 2015 Nov; 51(16):2465-72. . View in PubMed

Pilot study of intravenous melphalan combined with continuous infusion L-S,R-buthionine sulfoximine for children with recurrent neuroblastoma Pediatr Blood Cancer. 2015 Oct; 62(10):1739-46. . View in PubMed

Phase I Study of Vorinostat as a Radiation Sensitizer with 131I-Metaiodobenzylguanidine (131I-MIBG) for Patients with Relapsed or Refractory Neuroblastoma Clin Cancer Res. 2015 Jun 15; 21(12):2715-21. . View in PubMed

131I-metaiodobenzylguanidine with intensive chemotherapy and autologous stem cell transplantation for high-risk neuroblastomaA new approaches to neuroblastoma therapy (NANT) phase II study. Biol Blood Marrow Transplant. 2015 Apr; 21(4):673-81. . View in PubMed

Probable fatal drug interaction between intravenous fenretinide, ceftriaxone, and acetaminophen: a case report from a New Approaches to Neuroblastoma (NANT) Phase I study BMC Res Notes. 2014 Apr 23; 7:256. . View in PubMed

Phase I trial of fenretinide delivered orally in a novel organized lipid complex in patients with relapsed/refractory neuroblastoma: a report from the New Approaches to Neuroblastoma Therapy (NANT) consortium Pediatr Blood Cancer. 2013 Nov; 60(11):1801-8. . View in PubMed

Purged versus non-purged peripheral blood stem-cell transplantation for high-risk neuroblastoma (COG A3973): a randomised phase 3 trial Lancet Oncol. 2013 Sep; 14(10):999-1008. . View in PubMed

Semiquantitative mIBG scoring as a prognostic indicator in patients with stage 4 neuroblastoma: a report from the Children's oncology group J Nucl Med. 2013 Apr; 54(4):541-8. . View in PubMed

Clinical significance of tumor-associated inflammatory cells in metastatic neuroblastoma J Clin Oncol. 2012 Oct 01; 30(28):3525-32. . View in PubMed

Dose escalation study of no-carrier-added 131I-metaiodobenzylguanidine for relapsed or refractory neuroblastoma: new approaches to neuroblastoma therapy consortium trial J Nucl Med. 2012 Jul; 53(7):1155-63. . View in PubMed

Choroid plexus tumors; management, outcome, and association with the Li-Fraumeni syndrome: the Children's Hospital Los Angeles (CHLA) experience, 1991-2010 Pediatr Blood Cancer. 2012 Jun; 58(6):905-9. . View in PubMed

Phase I study of vincristine, irinotecan, and ¹³¹I-metaiodobenzylguanidine for patients with relapsed or refractory neuroblastoma: a new approaches to neuroblastoma therapy trial Clin Cancer Res. 2012 May 01; 18(9):2679-86. . View in PubMed

The significance of serial histopathology in a residual mass for outcome of intermediate risk stage 3 neuroblastoma Pediatr Blood Cancer. 2012 May; 58(5):675-81. . View in PubMed

Phase II study of oral capsular 4-hydroxyphenylretinamide (4-HPR/fenretinide) in pediatric patients with refractory or recurrent neuroblastoma: a report from the Children's Oncology Group Clin Cancer Res. 2011 Nov 01; 17(21):6858-66. . View in PubMed

Phase I trial of lestaurtinib for children with refractory neuroblastoma: a new approaches to neuroblastoma therapy consortium study Cancer Chemother Pharmacol. 2011 Oct; 68(4):1057-65. . View in PubMed

A phase I study of zoledronic acid and low-dose cyclophosphamide in recurrent/refractory neuroblastoma: a new approaches to neuroblastoma therapy (NANT) study Pediatr Blood Cancer. 2011 Aug; 57(2):275-82. . View in PubMed

Thyroid and hepatic function after high-dose 131 I-metaiodobenzylguanidine (131 I-MIBG) therapy for neuroblastoma Pediatr Blood Cancer. 2011 Feb; 56(2):191-201. . View in PubMed

Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma N Engl J Med. 2010 Sep 30; 363(14):1324-34. . View in PubMed

Treatment of primary CNS germinomatous germ cell tumors with chemotherapy prior to reduced dose whole ventricular and local boost irradiation Pediatr Blood Cancer. 2010 Jul 15; 55(1):42-6. . View in PubMed

Peripheral blood stem cell support for multiple cycles of dose intensive induction therapy is feasible with little risk of tumor contamination in advanced stage neuroblastoma: a report from the Childrens Oncology Group Pediatr Blood Cancer. 2010 Apr; 54(4):596-602. . View in PubMed

Comparison of iodine-123 metaiodobenzylguanidine (MIBG) scan and [18F]fluorodeoxyglucose positron emission tomography to evaluate response after iodine-131 MIBG therapy for relapsed neuroblastoma J Clin Oncol. 2009 Nov 10; 27(32):5343-9. . View in PubMed

Phase I trial of oral irinotecan and temozolomide for children with relapsed high-risk neuroblastoma: a new approach to neuroblastoma therapy consortium study J Clin Oncol. 2009 Mar 10; 27(8):1290-6. . View in PubMed

Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children's oncology group study J Clin Oncol. 2009 Mar 01; 27(7):1007-13. . View in PubMed

Iodine-131--metaiodobenzylguanidine double infusion with autologous stem-cell rescue for neuroblastoma: a new approaches to neuroblastoma therapy phase I study J Clin Oncol. 2009 Mar 01; 27(7):1020-5. . View in PubMed

Outcome of high-risk stage 3 neuroblastoma with myeloablative therapy and 13-cis-retinoic acid: a report from the Children's Oncology Group Pediatr Blood Cancer. 2009 Jan; 52(1):44-50. . View in PubMed

Phase I trial of oral fenretinide in children with high-risk solid tumors: a report from the Children's Oncology Group (CCG 09709) J Clin Oncol. 2006 Jul 20; 24(21):3423-30. . View in PubMed

Phase I dose escalation of iodine-131-metaiodobenzylguanidine with myeloablative chemotherapy and autologous stem-cell transplantation in refractory neuroblastoma: a new approaches to Neuroblastoma Therapy Consortium Study J Clin Oncol. 2006 Jan 20; 24(3):500-6. . View in PubMed

A Phase I study of concurrent RMP-7 and carboplatin with radiation therapy for children with newly diagnosed brainstem gliomas Cancer. 2005 Nov 01; 104(9):1968-74. . View in PubMed

Phase 1 study of concurrent RMP-7 and carboplatin with radiotherapy for children with newly diagnosed brainstem gliomas Cancer. 2005 Sep 15; 104(6):1281-7. . View in PubMed

Approaches to treatment for extraocular retinoblastoma: Children's Hospital Los Angeles experience J Pediatr Hematol Oncol. 2004 Jan; 26(1):31-4. . View in PubMed

Retinoid therapy of high-risk neuroblastoma Cancer Lett. 2003 Jul 18; 197(1-2):185-92. . View in PubMed

Successful multimodality therapy of recurrent multifocal juvenile granulosa cell tumor of the ovary J Pediatr Hematol Oncol. 2002 Mar-Apr; 24(3):229-33. . View in PubMed

Powered by SC CTSI
Go to Top